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Summary
 
The role of CD40 ligand (CD40L) in CD8 T cell activation was assessed by tracking antigen-
specific T cells in vivo using both adoptive transfer of T cell receptor transgenic T cells and
major histocompatibility complex (MHC) class I tetramers. Soluble antigen immunization in-
duced entry of CD8 cells into the intestinal mucosa and cytotoxic T lymphocyte (CTL) differ-
entiation, whereas CD8 cells in secondary lymphoid tissue proliferated but were not cytolytic.
Immunization concurrent with CD40L blockade or in the absence of CD40 demonstrated that
accumulation of CD8 T cells in the mucosa was CD40L dependent. Furthermore, activation
was mediated through CD40L expressed by the CD8 cells, since inhibition by anti-CD40L
monoclonal antibodies occurred after adoptive transfer to CD40L-deficient mice. However,
mucosal CD8 T cells in normal and CD40
 
2
 
/
 
2
 
 mice were equivalent killers, indicating that
CD40L was not required for CTL differentiation. Appearance of virus-specific mucosal, but
not splenic, CD8 cells also relied heavily on CD40–CD40L interactions. The mucosal CTL re-
sponse of transferred CD8 T cells was MHC class II and interleukin 12 independent. The re-
sults established a novel pathway of direct CD40L-mediated CD8 T cell activation.
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cell activation is dependent on multiple signaling events
that occur through engagement of cell-surface recep-
tors. Prime among these is triggering the TCR via an anti-
genic peptide–MHC complex, which can result in T cell
activation (1, 2). However, this signal alone generally re-
sults in a transient, nonproductive immune response (3, 4).
Costimulatory signals are required in addition to TCR en-
gagement to drive the response to fruition (5). Inflamma-
tory mediators generated during microbial infections or by
adjuvants can induce the required costimulation (6–8). For
example, activation of CD4 T cells with antigen in the ab-
sence of adjuvant does not lead to induction of sufficient
help to produce an antibody response (3, 4). However, in
the presence of adjuvant, encounter with antigen leads to
antibody production (3, 4). The effect of adjuvants can be
at the level of the antigen-presenting cell (APC) by up-
regulation of CD28-costimulatory ligands such as B7,
and by induction of proinflammatory cytokines (6, 7). An-
other important costimulatory receptor–ligand interaction
is CD40–CD40L (9, 10). CD40L (CD154) is upregulated
on activated CD4 T cells and interacts with CD40 expressed
by APCs and by B cells (11–13). Blockade or absence of
CD40L or CD40 impairs T cell help for B cell activation
(14, 15). Furthermore, activation of APCs via inflammation
can be mimicked by triggering of CD40 with agonist
ligands or antibodies (16–18).
Although the importance of CD40L-mediated CD4 T
cell interactions with B cells is recognized, it has been less
clear what role CD40 plays in CD8 T cell activation (9).
Recent reports indicate that CD40L–CD40-mediated acti-
vation of dendritic cells (DCs) by antigen-specific CD4 T
cells is essential for subsequent priming of CD8 T cells
(19–21). That is, in those cases where T cell help is re-
quired to generate a productive CD8 T cell response, trig-
gering of the DCs by CD4 T cells is necessary before DC
encounter with an antigen-specific CD8 T cell. The prop-
erties engendered to the DC that are involved in CD8 T
cell activation are not known, but possibilities are the up-
regulation of B7 costimulators and/or cytokines such as IL-
12 (22). Although activated CD8 T cells can themselves
express CD40L (23–25), there is little evidence for a direct
functional interaction between CD8 T cell CD40L and
CD40 expressed by APCs or other cell types (9).
Using an adoptive transfer system in which ovalbumin
(OVA)-specific CD8 T cells (OT-I cells) are transferred to
normal mice, we have shown that immunization with solu-
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6; CFSE, carboxyfluorescein
diacetate succinimidyl ester; DC, dendritic cell; IEL, intraepithelial lym-
phocyte; LP, lamina propria; LPL, LP lymphocyte; MLN, mesenteric
lymph node; N, VSV nucleoprotein; PLN, peripheral LN; PP, Peyer’s patch;
RAG, recombination-activating gene; VSV, vesicular stomatitis virus. 
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ble (s)OVA in the absence of adjuvant results in proliferation
and phenotypic differentiation of OT-I cells residing in
secondary lymphoid tissues (26). However, only low levels
of CTL activity are induced in these OT-I cells. In the
same animals, OT-I cells that had migrated to the intestinal
mucosa after activation and were present in the lamina pro-
pria (LP) and intraepithelial lymphocyte (IEL) compart-
ment became potent antigen-specific CTLs (26). The basis
for this dichotomy in the outcome of primary peripheral
versus mucosal CD8 T cell responses is unknown. One
possibility is that the inflammatory nature of the intestinal
mucosa generates signals that induce mucosal APCs to be-
come competent to drive CTL responses even when pre-
senting soluble antigen. This theory was supported by our
finding that costimulation via B7-1 played a larger role in
the mucosal than in the peripheral OT-I response to sOVA
(26). With regard to CD8 cells in secondary lymphoid tis-
sues, this system also allowed the separation in vivo of the
induction of proliferation from the induction of CTL ac-
tivity. Using this model, as well as MHC tetramers to iden-
tify endogenous virus antigen-specific CD8 T cells, we have
now analyzed the role of CD40–CD40L interactions in pri-
mary mucosal and peripheral CTL induction. The results
provide evidence for a critical role for CD40L in the optimal
generation of a mucosal CD8 T cell response.
 
Materials and Methods
 
Mice.
 
C57BL/6J (Ly5.1), C57BL/6 (B6)–IL-12
 
b
 
tm1Jm
 
 (27), and
B6-Tnfsf5
 
tm1Imx
 
 (CD40L
 
2
 
/
 
2
 
; reference 28) mice were purchased
from The Jackson Laboratory. C57BL/6TacfBr-[KO]A
 
b
 
b
 
 mice
(29) were purchased from Taconic Farms Inc. B6-Ly5.2 mice
were obtained from Charles River Laboratories through the
National Cancer Institute animal program. The OT-I mouse line
was provided by W.R. Heath (The Walter and Eliza Hall Insti-
tute of Medical Research, Parkville, Australia) and F. Carbone
(Monash Medical School, Prahran, Victoria, Australia) (30) and
was maintained as a B6-Ly5.2 or B6-Ly5.1 line on a recombina-
tion-activating gene (RAG)
 
2
 
/
 
2
 
 background. B6-CD40
 
2
 
/
 
2
 
 mice
(14) were provided by Dr. Hitoshi Kikutani (Osaka University,
Osaka, Japan) via Dr. Nancy Philips (University of Massachusetts
Medical Center, Worcester, MA).
 
Adoptive Transfer.
 
This method was adopted from Kearney et
al. (3). 2.5–4 
 
3
 
 10
 
6
 
 pooled CD8 LN cells from OT-I–RAG
 
2
 
/
 
2
 
(Ly5.1 or Ly5.2) mice were injected intravenously into B6 (Ly5.1
or Ly5.2) mice. 2 d later 5 mg of OVA (Grade VI; Sigma Chem-
ical Co.) was administered by intraperitoneal injection. Lympho-
cytes were isolated at the indicated times and analyzed for the
presence of transferred cells by flow cytometric detection of Ly5
differences. Antibody treatments were performed by intraperito-
neal injection of 200 
 
m
 
g of MR1 (anti-CD40L) or hamster Ig as
control (11). MR1 was provided by Dr. R. Noelle, Dartmouth
Medical School, Hanover, NH. Injections were given daily start-
ing 1 d before immunization. Cells were labeled with 5- (and
-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; Mo-
lecular Probes, Inc.) at a concentration of 5 
 
m
 
m for 10 min at
37
 
8
 
C (31, 32). Each experiment was performed a minimum of
three times.
 
Detection of Vesicular Stomatitis Virus–specific CD8 T Cells with
MHC Tetramers.
 
Mice were infected by intravenous injection
 
of 1 
 
3
 
 10
 
6
 
 PFU of vesicular stomatitis virus (VSV), Indiana sero-
type. 6 d later lymphocytes were isolated, and VSV nucleoprotein
(N)-specific CD8 T cells were detected using H-2K
 
b
 
 tetramers
containing the N protein–derived peptide RGYVYQGL, or as a
control the OVA-derived peptide SIINFEKL (Research Genet-
ics) (33). MHC tetramers were produced essentially as described
previously (34, 35). Briefly, H-2K
 
b
 
 containing the BirA-depen-
dent biotinylation substrate sequence was folded in the presence
of human 
 
b
 
2-microglobulin and the N peptide. Biotinylation
was performed with biotin–protein ligase (Avidity). Tetramers
were then produced from biotinylated HPLC–purified mono-
mers by addition of streptavidin–allophycocyanin (Molecular
Probes, Inc.).
 
Isolation of Lymphocyte Populations.
 
IELs and LP cells were
isolated as described previously (36, 37). For cytotoxicity assays,
panning of Percoll-fractionated IELs on anti-CD8 mAb–coated
plates was performed to remove contaminating epithelial cells.
Without panning, lytic activity of IELs is less consistent between
replicates, but overall activity is similar to that of panned cells.
Lytic activity of LPLs is measured without prior panning and is
similar to that of IELs, indicating that the anti-CD8 panning step
does not effect lytic function (data not shown). LNs and spleens
were removed, and single cell suspensions were prepared using a
tissue homogenizer. Peripheral LNs included brachial, axillary,
and superficial inguinal nodes. The resulting preparation was fil-
tered through Nitex, and the filtrate was centrifuged to pellet the
cells.
 
Immunofluorescence Analysis.
 
Lymphocytes were resuspended
in PBS, 0.2% BSA, 0.1% NaN
 
3
 
 (PBS/BSA/NaN
 
3
 
) at a concen-
tration of 10
 
6
 
–10
 
7
 
 cells/ml followed by incubation at 4
 
8
 
C for 30
min with 100 
 
m
 
l of properly diluted mAb. The mAbs were either
directly labeled with FITC, PE, Cy5, allophycocyanin, or were
biotinylated. For the latter, avidin-PE-Cy7 (Caltag Laboratories)
was used as a secondary reagent for detection. After staining, the
cells were washed twice with PBS/BSA/NaN
 
3
 
 and fixed in 3%
paraformaldehyde in PBS. Relative fluorescence intensities were
then measured with a FACSCalibur™ (Becton Dickinson). Data
were analyzed using WinMDI software (Joseph Trotter, Scripps
Clinic, La Jolla, CA).
 
Measurement of Cytolytic Activity.
 
Cytolytic activity was mea-
sured using (
 
51
 
Cr)sodium chromate–labeled EL4 cells (an H-2
 
b
 
thymoma), with or without the addition of 10 
 
m
 
g/ml of the
OVA-derived peptide SIINFEKL. Serial dilutions of effector cells
were incubated in 96-well round-bottomed microtiter plates
with 2.5 
 
3
 
 10
 
3
 
 target cells for 6 h at 37
 
8
 
C. Percent specific lysis
was calculated as: 100 
 
3
 
 [(cpm released with effectors) 
 
2
 
 (cpm
released alone)]/[(cpm released by detergent) 
 
2
 
 (cpm released
alone)].
 
Results
 
Blockade of CD40L Inhibits OT-I Accumulation in Mucosal
Tissues.
 
Our previous results indicate that adoptively trans-
ferred OVA-specific T cells migrating into the intestinal
mucosa become potent CTLs after immunization with OVA.
To test whether CD40–CD40L interactions were involved
in this activation, we treated mice during immunization
with a blocking mAb specific for CD40L (11). Naive OT-I
cells do not enter the intestinal mucosa (26, 38) but a small
population of naive cells (
 
z
 
0.5%) can be detected in the
peripheral LNs (PLNs) and mesenteric LNs (MLNs) by vir-
tue of differences in Ly5.1/Ly5.2 expression between the 
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transferred and host lymphocytes (Fig. 1). 3 d after intra-
peritoneal immunization with sOVA, a large increase in
OT-I cells in PLNs and MLNs was observed. Although the
magnitude of this response is dependent on antigen dose,
immunization with 0.5 mg sOVA resulted in detectable T
cell activation and migration to the mucosa (data not shown).
Responses in MLNs were partially inhibited (
 
z
 
30%), whereas
PLN OT-I responses were not affected (Figs. 1, 2 A, and
3). Although the inhibition of the MLN response is not
impressive, it was consistently observed, as was the lack of
inhibition of the PLN response. However, treatment with
anti-CD40L mAb resulted in 
 
z
 
70–80% inhibition of ap-
pearance of OT-I cells in the IELs (Fig. 1) and LP (Fig. 2 B)
compartments. This inhibition was not merely a kinetic
delay in the response, as the effect of early anti-CD40L
blockade was maintained throughout the response (8 d and
longer after immunization; data not shown). Thus, there
was an apparent requirement for CD40–CD40L interac-
tions to generate an optimal mucosal CD8 T cell response.
 
CD40L Delivers Proliferative Signals to CD8 T Cells.
 
The effect of anti-CD40L mAb on mucosal OT-I accumu-
lation could have been due to inhibition of migration or of
proliferation. In addition, inhibition of proliferation outside
of the mucosa could result in fewer cells migrating to the
mucosa. To determine the point at which CD40L inter-
actions were involved in activation, we transferred CFSE-
labeled OT-I cells and then immunized with OVA in the
presence or absence of anti-CD40L mAb. 3 d after immu-
nization, lymphoid tissues were analyzed for the presence
of donor cells and their CFSE fluorescence was measured.
CFSE is distributed equally between daughter cells upon
division and can be detected over nine divisions (i.e., no
fluorescence after nine divisions [31, 32]). In all sites, OT-I
cells from control mice had divided at least nine times and
thus retained no fluorescence above background (Fig. 2, A
and B). This was true even at time points earlier than 72 h
when fewer cells had appeared in the intestinal mucosa, in-
dicating that substantial proliferation of OT-I cells had oc-
curred elsewhere before entry into the mucosa (data not
shown). Transferred cells in PLNs from MR1-treated mice
also exhibited little fluorescence, indicating that the cells
had divided at least nine times, and that CD40L blockade
had not greatly affected the proliferation of cells in the
PLNs. In MLNs, 
 
z
 
40% of the cells from anti-CD40L–
treated mice had undergone eight divisions, at least one less
than control OT-I cells. In the LP from MR1-treated
mice, 
 
z
 
50% of the OT-I cells had divided less than nine
times, with 28% having divided seven times, and 7% hav-
ing undergone six divisions. In IELs from MR1-treated
mice, 
 
z
 
60% of the cells had undergone less than nine divi-
sions, and 22% had divided seven times. This inhibition of
Figure 1. CD40L blockade inhibits mucosal CD8 T cell expansion.
B6-Ly5.1 OT-I–RAG2/2 cells (2.5 3 106) were transferred to B6-Ly5.2
mice, and 2 d later mice were immunized with 5 mg OVA by intraperi-
toneal injection, or were not immunized (NO ANTIGEN). 1 d before
immunization and continuing each day, mice were treated with 200 mg
of MR1 (aCD40L) or control hamster Ig. 3 d after immunization, lym-
phocytes from the indicated tissues were analyzed by flow cytometry for
the presence of donor cells by virtue of Ly5.1 and CD8 expression.
Figure 2. Mucosa-specific inhibition of CD8 T cell expansion by
CD40L blockade. 4 3 106 naive OT-I–RAG2/2 cells (Ly5.1) were la-
beled with CFSE and transferred to normal mice (Ly5.2). Mice were
treated daily with aCD40L or control antibody starting at 1 d before im-
munization. 2 d after transfer mice were immunized with 5 mg OVA,
and 3 d later PLN and MLN cells (A) and LP cells and IEL (B) were iso-
lated and analyzed by flow cytometry. CFSE staining of the gated donor
cells is shown (right), with open histograms representing aCD40L-treated
mice and filled histograms representing control antibody-treated mice.
The asterisked histogram indicates CFSE-labeled OT-I cells from the
PLNs of naive mice. 
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proliferation correlated well with the decreased percentage
and total cell number (data not shown) of OT-I cells in LP
and IELs. These results suggested that CD40L-mediated
proliferative signals, whether delivered within or outside of
the mucosa, were important for generation of the mucosal
CD8 response.
The results thus far demonstrated a role for CD40L in
CD8 T cell activation, but did not indicate whether this ef-
fect was direct or indirect. To test this, we transferred OT-I–
RAG
 
2
 
/
 
2
 
 cells into CD40L-deficient mice and attempted
to block activation with MR1. In this experiment, only the
transferred CD8 T cells were capable of expressing CD40L,
so that any inhibitory effect must be mediated at the level
of the OT-I cells. After OT-I cell transfer, immunization
of CD40L
 
2
 
/
 
2
 
 mice with sOVA resulted in substantial pro-
liferation in the periphery and appearance of OT-I cells in
the LP (Fig. 3). Treatment with anti-CD40L mAb resulted
in partial inhibition of OT-I accumulation in MLNs and
much greater inhibition of OT-I accumulation in the LP
(Fig. 3). Little inhibition of OT-I expansion in PLNs was
observed (data not shown). These results were similar to
those obtained in CD40L-competent mice (Figs. 1 and 2),
and indicated that CD40L expressed by CD8 T cells was
responsible for activation of OT-I cells destined for the
mucosa.
 
CD40 Expression Is Required for Mucosal CD8 T Cell Re-
sponses of Transferred or Endogenous CD8 T Cells.
 
Although
anti-CD40L mAb treatments have been widely employed
to test in vivo function, it was possible that mAb binding to
CD40L directed untoward effects on the T cells. There-
fore, we performed adoptive transfer and immunization in
mice lacking CD40 (Fig. 4). 4 d after antigen administra-
tion, substantial populations of OT-I cells were detected in
PLNs, MLNs, LP, and IELs of normal mice. However, in
the absence of CD40, OT-I cells were reduced by 
 
z
 
80%
in IELs and LP, just as they were with MR1 treatment. In-
terestingly, the inhibition of OT-I cell expansion in both
PLNs and MLNs was greater than that observed with MR1
treatment. However, a difference remained between PLNs
(
 
z
 
40% reduction) versus MLNs (
 
z
 
75% reduction).
To further examine the role of CD40 in mucosal CD8 T
cell responses, we visualized the response of endogenous an-
tiviral CD8 T cells using MHC tetramers. B6 or CD40
 
2
 
/
 
2
 
mice were infected with VSV, and 6 d later spleen cells,
LPLs, and IELs were isolated. N-specific CD8 T cells were
identified using H-2K
 
b
 
–N peptide MHC tetramers. In nor-
mal mice, N-specific cells consistently comprised 
 
z
 
10% of
the splenic CD8 T cells, whereas in the CD40
 
2
 
/
 
2
 
 mouse
shown the response was partially inhibited, with 4.5% of
the CD8 cells reactive with N-peptide (Fig. 5). However,
the difference observed in the splenic response between
control (10.4 
 
6
 
 1.8, 
 
n
 
 
 
5
 
 6) versus CD40
 
2
 
/
 
2
 
 (7.6 
 
6
 
 2; 
 
n
 
 
 
5
 
6) mice was not statistically significant. In contrast, the anti-
VSV CD8 response in LP was greatly inhibited in the ab-
Figure 3. Direct inhibition of T cell expansion by CD8 T cell CD40L
blockade. 2.5 3 106 naive OT-I–RAG2/2 cells (Ly5.2) were transferred
to Ly5.1 CD40L2/2 mice. Mice were treated daily with aCD40L or con-
trol antibody starting at 1 d before immunization. 2 d after transfer mice
were immunized with 5 mg OVA, and 3 d later MLN and LP cells were
isolated and analyzed by flow cytometry for the presence of donor cells by
analysis of Ly5.2 and CD8 expression. In unimmunized mice, OT-I cells
comprised 0.4% of MLN cells and were undetectable in LP cells (data not
shown).
Figure 4. Optimal proliferation of activated mucosal CD8 T cells re-
quires CD40. 4 3 106 naive OT-I–RAG2/2 cells (Ly5.2) were trans-
ferred to C57BL/6J or B6-CD402/2 mice, and 2 d later the mice were
immunized with 5 mg OVA intraperitoneally. 4 d later, lymphocytes
were isolated from the indicated sites and analyzed for the presence of do-
nor CD8 T cells by flow cytometry. 
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sence of CD40. In the experiment shown, 21% of LP CD8
cells from control mice were N-specific, while only 2.5%
were N-specific in CD40
 
2
 
/
 
2
 
 mice (Fig. 5). The difference
between the response in control mice (19.7 
 
6
 
 0.8, 
 
n
 
 
 
5
 
 6)
versus CD40
 
2
 
/
 
2
 
 mice (4 
 
6
 
 0.6; 
 
n
 
 
 
5
 
 6) was highly signifi-
cant (
 
P
 
 
 
5
 
 0.001) and was independent of total CD8 cell
numbers (data not shown). Although we do not yet know
whether CD40L expressed by antiviral CD8 cells is in-
volved in activation, the results nevertheless demonstrated
the importance of CD40–CD40L interactions in the mu-
cosal antiviral CD8 response.
 
Generation of Mucosal OT-I CTLs Is CD40 Independent.
 
The adoptive transfer system allows a comparison of lytic
activity on a per cell basis, and so whether CD40L trigger-
ing results in enhanced lytic activity was tested. We ana-
lyzed CTL activity of transferred OT-I cells from IELs and
spleen from immunized, normal, or CD40
 
2
 
/
 
2 mice (Fig. 6).
sOVA immunization induced poor lytic activity in OT-I
cells in spleen despite their activated state, as determined
by phenotype and proliferation (data not shown, and refer-
ence 26). In contrast, sOVA immunization resulted in ap-
pearance of potent OT-I IEL effectors (Fig. 6). In the ab-
sence of CD40, OT-I proliferation was severely inhibited
in the IEL compartment, as shown in Fig. 4. Nevertheless,
when the lytic activity of OT-I effectors was compared on
a per cell basis, OT-I IELs in CD402/2 mice were equally
effective at inducing antigen-specific lysis as IELs from
control mice. This result demonstrated that CD40–CD40L
interactions were essential for optimal induction of prolif-
eration of CD8 T cells, but that differentiation to CTLs in
the intestinal mucosa was CD40 and CD40L independent.
MHC Class II–selected CD4 T Cells or IL-12 Are Not Re-
quired for Induction of Peripheral or Mucosal CTLs. The MR1
blocking studies predicted that CD4 cells were not likely to
be involved in the sOVA activation of mucosal OT-I cells.
To test this directly, the lytic activity of OT-I IELs was
measured after adoptive transfer and immunization of MHC
class II–deficient mice. The absence of MHC class II had
no effect on generation of CTLs in the mucosa (Fig. 7).
Proliferation of OT-I cells in MHC class II–deficient mice
was also no different from that observed in normal mice
Figure 5. Amplification of the mucosal antiviral CD8 T cell response
requires CD40. B6 or CD402/2 mice were infected by intravenous injec-
tion of 1 3 106 PFU of VSV. 6 d later, spleen and LP cells were isolated
and stained for three-color flow cytometry with allophycocyanin-labeled
H-2Kb–N peptide tetramers (N-tet-APC), anti-CD8–PE, and anti-
CD11a–FITC. CD81 cells were positively gated and then analyzed for
tetramer and CD11a staining. Negative control staining of cells from in-
fected mice was performed with H-2Kb–OVA peptide tetramers, and no
staining was observed (data not shown).
Figure 6. Mucosa-specific induction of CD8 lytic activity does not re-
quire CD40. Naive OT-I–RAG2/2 cells (Ly5.2) were transferred to
C57BL/6J or B6-CD402/2 mice, and 2 d later the mice were immunized
intraperitoneally with 5 mg OVA. 3 d later, lymphocytes were isolated
and tested for cytolytic activity against SIINFEKL-coated (filled symbols)
or untreated (open symbols) 51Cr-labeled EL4 target cells. The effector to
target ratios shown indicate actual percentages of OT-I cells based on
flow cytometric data. d, s: B6 IELs; j, h: CD402/2 IELs; ., ,: B6
spleen cells. Spontaneous 51Cr release was ,10%.
Figure 7. Mucosal induction of CD8 T cell lytic activity occurs inde-
pendently of MHC class II and IL-12. Naive OT-I–RAG2/2 cells (4 3
106; Ly5.2) were transferred to C57BL/6J, or B6–Abb2/2, or B6–IL-122/2
mice, and 2 d later the mice were immunized intraperitoneally with 5 mg
OVA. 3 d later IELs were isolated and tested for cytolytic activity against
SIINFEKL-coated 51Cr-labeled EL4 target cells. The effector to target ra-
tios shown indicate actual percentages of OT-I cells based on flow cyto-
metric data. Host mice were (A) j, B6; ., MHC class II2/2; (B) d, B6;
r, IL-122/2. Specific lysis in the absence of peptide was ,10%. Sponta-
neous 51Cr release was ,10%.1280 CD8 T Cell Activation Via CD40L
(data not shown). Since IL-12 is produced by activated
APCs and has been suggested to be involved in potentia-
tion of CTL activity (39–42), we also performed transfers
into mice lacking IL-12. The absence of IL-12 did not af-
fect the induction of lytic activity or the proliferation of
OT-I cells in the intestinal mucosa (Fig. 7).
Discussion
The results presented here identified for the first time a
critical role for CD40–CD40L interactions in mucosal
CD8 T cell responses. Blockade or removal of CD40L in-
teractions demonstrated a more stringent requirement for
CD40–CD40L engagement to generate a CD8 response in
mucosal effector sites (LP, IELs) compared with responses
in peripheral secondary lymphoid tissue. This was true for
the response of adoptively transferred OT-I cells (Figs. 1–4),
as well as for an endogenous antiviral CD8 T cell response
(Fig. 5). Recently, it was reported that the splenic anti-
VSV CTL response was CD40 independent as determined
by measuring lytic activity (43). Our present results using
MHC tetramer staining corroborate these findings (Fig. 5).
Perhaps more importantly, our data showed that despite
the fact that the splenic anti-VSV CD8 response was CD40
independent, the LP CD8 response had a stringent require-
ment for CD40. These results demonstrated a role for tis-
sue-specific regulation of the CD8 immune response via
CD40. The results also suggested, but did not prove, that
CD8 cells migrating to the mucosa encountered APCs in
the LP, which induced further proliferation and differentia-
tion. There are few, if any, professional APCs in the intes-
tinal epithelium, so the inhibition of the IEL response by
CD40–CD40L blockade or absence was likely the result of
a decrease in the LPL response and/or the peripheral re-
sponse, thereby resulting in fewer cells available for migra-
tion to the epithelium. Indeed, the inhibition of the LPL
response always paralleled the decrease in the IEL response.
If the mucosal response is in fact modulated by interac-
tion of migrating CD8 cells with LP APCs, then the result-
ing effects could be linked to the status of APCs in the LP.
That is, LP APCs may be at a heightened activated state
compared with those in nonmucosal areas. This possibility
was supported by the induction of CTL activity in mucosal
effector sites but not in peripheral tissues. DCs from the gut
migrate to MLNs (44, 45), and this could form the basis of
the observed role for CD40L in that site. However, signals
in addition to CD40L triggering must be involved in CTL
induction, since activated OT-I cells in MLNs exhibited
poor lytic activity (data not shown). Overall, the results
supported a generalized role for CD40–CD40L interactions
in amplification of intestinal CD8 T cell responses, whether
or not the relevant CD8 T cell–APC interaction occurred
in the mucosa.
Our finding that CD40L expressed by activated OT-I
cells was interacting with CD40 expressed by APCs made
sense, considering that MHC class II–restricted CD4 T
cells were not required for the OT-I response. The impor-
tance of CD40L expressed by OT-I cells was unequivocally
established by showing that inhibition of OT-I expansion
by CD40L blockade occurred when OT-I cells were the
only cells capable of expressing CD40L (Fig. 3). However,
this finding does not preclude an indirect role for CD4 T
cells, when they are present, in CTL expansion via an ef-
fect on APCs. Thus, CD4 cells could induce upregulation
of CD40 on APCs, which would subsequently interact
with CD40L expressed by CD8 T cells. Nevertheless, the
recent demonstration that CD8 T cells can directly activate
dendritic cells (43) supports the concept that some CD8 re-
sponses do not require CD4 T cells to activate APCs.
In all other in vivo responses examined thus far, CD40L
expressed by CD4 T cells was critical for CD8 T cell acti-
vation (19–21, 46, 47). However, in contrast to the system
in which CD40 triggering is required to induce CTLs to
OVA-loaded spleen cells (20), induction of mucosal CTLs
to soluble antigen was CD40 independent. That is, despite
the fact that the increase in OT-I cells in LP and IELs was
greatly inhibited by CD40L blockade, the lytic activity of
the remaining cells was not affected. Thus, although CD40
triggering in some situations can drive CTL differentiation
(21), this is apparently not a requisite step for mucosal CTL
induction. It should be noted that in previous studies it was
not possible to determine the effect of CD40 on prolifera-
tion versus CTL differentiation, since antigen-specific T
cells were not quantified. The importance of CD40/
CD40L in the mucosal CD8 T cell response indicates that
the nature of the CD40 expressed by intestinal APCs may
be distinct from that of APCs in nonmucosal sites, perhaps
in terms of level of expression as well as activation status of
the cell. The significant numbers of activated B cells in the
LP could participate in the response as APCs. Further, the
density and/or anatomy of the APC network in the LP
may regulate T cell interactions differently from those oc-
curring in secondary lymphoid tissue.
Although we do not yet know the factors required for
mucosal induction of CTLs, we showed here that IL-12
was not essential. Exogenous IL-12 augments alloreactive
CTL activity in vitro (39) and in vivo (41). Yet, it is not
clear from these studies whether IL-12 acts directly on
CD8 T cells or affects CD4 T cells which then influence
the CTL response. Moreover, the primary alloreactive
CTL response in vivo was unaffected in IL-12–deficient
mice (27). In another report, low doses of IL-12 increased
the number of CD8 cells in lymphocytic choriomeningitis
virus–infected mice, whereas high doses of IL-12 inhibited
the CTL response (42). Thus, although splenic CD8 cells
may respond to exogenous IL-12, it remains unclear
whether IL-12 is involved in systemic CD8 T cell immu-
nity. In the case of mucosal T cell responses, IL-12 appears
to play a significant role. In a model of colitis in which
IFN-g–producing Th1 cells are involved, inhibition of
IL-12 results in abrogation of the disease (48). Furthermore,
inhibition of CD40L–CD40 interaction inhibited the in-
duction of the disease by blocking priming of Th1 cells by
IL-12 (49). IL-12 may also play a role in some mucosal
CD8 responses. Mucosal immunization of mice with a
multideterminant HIV peptide results in the appearance of1281 Lefrançois et al.
antigen-specific CTLs in spleen, Peyer’s patches (PPs), and
LP. However, CTL priming was completely abrogated
when IL-12 was blocked or IFN-g was absent (50). In our
system, primary mucosal CTL development was IL-12 in-
dependent. This finding may be related to the demonstra-
tion that this response was also CD4 T cell independent,
while the colitis model and the response to the HIV pep-
tide require CD4 T cells. Therefore, as discussed above, the
requirement for IL-12 in CD8 responses may be indirect
and related to the action of this cytokine on CD4 T cells.
Our findings support a model for mucosal CD8 T cell
activation in which sequential encounters with APCs may
occur. As shown here for sOVA immunization and VSV
infection, CD40–CD40L interaction allowed a significant
amplification of the mucosal CD8 response. This system
could provide a powerful mechanism for potentiation of
mucosal immune responses. The goal of the immune sys-
tem is to send functional CTLs to sites of potential patho-
gen entry, the intestine being foremost on this list. When
the intestinal mucosa is infected, antigens are most likely
presented to T cells in the draining organized secondary
lymphoid tissue such as PPs and MLNs, followed by migra-
tion of activated T cells to the LP. Our hypothesis suggests
that upon entry into the LP, CD8 T cells may reencounter
antigen presented by APCs and receive further proliferative
and differentiative signals. This theory predicts a second
level of regulation for CD8 T cells patrolling the mucosa:
i.e., if antigen is not encountered in the mucosa, further ac-
tivation of CD8 T cells does not occur, thereby conserving
resources and decreasing the opportunity for destructive
autoimmune reactions. Deciphering the specialized signals
for T cell activation in the intestinal mucosa will provide
tools for manipulating inflammatory bowel disease and for
potentiation of mucosal vaccination and immune barrier
function.
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